StockData
Context Therapeutics Inc. logo

Context Therapeutics Inc. (CNTX) stock

CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.17−0.00 (-2.69%)

Close on Nov 18, 2026Market cap $15.29MP/E –Yield –

Context Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Context Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$34.03M. For fiscal 2025 it was -$26.42M. The highest annual figure on record is -$8.80M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.42M–
FY2024Dec 31, 2024-$14.56M–
FY2023Dec 31, 2023-$21.05M–
FY2022Dec 31, 2022-$13.59M–
FY2021Dec 31, 2021-$8.80M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.04M–
Q1 FY2026Mar 31, 2026-$11.47M–
Q4 FY2025Dec 31, 2025-$8.94M–
Q3 FY2025Sep 30, 2025-$6.58M–
Q2 FY2025Jun 30, 2025-$5.84M–
Q1 FY2025Mar 31, 2025-$5.06M–
Q4 FY2024Dec 31, 2024-$4.91M–
Q3 FY2024Sep 30, 2024-$1.94M–
Q2 FY2024Jun 30, 2024-$3.36M–
Q1 FY2024Mar 31, 2024-$4.36M–
Q4 FY2023Dec 31, 2023-$7.23M–
Q3 FY2023Sep 30, 2023-$3.46M–
Q2 FY2023Jun 30, 2023-$4.63M–
Q1 FY2023Mar 31, 2023-$5.73M–
Q4 FY2022Dec 31, 2022-$3.93M–
Q3 FY2022Sep 30, 2022-$2.99M–
Q2 FY2022Jun 30, 2022-$2.81M–
Q1 FY2022Mar 31, 2022-$3.86M–
Q4 FY2021Dec 31, 2021-$4.96M–
Q3 FY2021Sep 30, 2021-$43.63K–
Q2 FY2021Jun 30, 2021-$2.08M–
Q1 FY2021Mar 31, 2021-$1.72M–

More Context Therapeutics figures

See a number that looks wrong?